Unknown

Dataset Information

0

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.


ABSTRACT: OBJECTIVES:Treatment options for preventing vaso-occlusive crises (VOC) among patients with sickle cell disease (SCD) are limited, especially if hydroxyurea treatment has failed or is contraindicated. A systematic literature review (SLR) and network meta-analysis (NMA) were conducted to evaluate the efficacy and safety of crizanlizumab for older adolescent and adult (?16 years old) SCD patients. METHODS:The SLR included randomised controlled trials (RCTs) and uncontrolled studies. Bayesian NMA of VOC, all-cause hospitalisation days and adverse events were conducted. RESULTS:The SLR identified 51 studies and 9 RCTs on 14 treatments that met the NMA inclusion criteria. The NMA found that crizanlizumab 5.0?mg/kg was associated with a reduction in VOC (HR 0.55, 95% credible interval (0.43, 0.69); Bayesian probability of superiority >0.99), all-cause hospitalisation days (0.58 (0.50, 0.68); >0.99) and no evidence of difference on adverse events (0.91 (0.59, 1.43) 0.66) or serious adverse events (0.93 (0.47, 1.87); 0.59) compared with placebo. The HR for reduction in VOC for crizanlizumab relative to L-glutamine was (0.67 (0.50, 0.88); >0.99). These results were sensitive to assumptions regarding whether patient age is an effect modifier. CONCLUSIONS:This NMA provides preliminary evidence comparing the efficacy of crizanlizumab with other treatments for VOC prevention.

SUBMITTER: Thom H 

PROVIDER: S-EPMC7500297 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.

Thom Howard H   Jansen Jeroen J   Shafrin Jason J   Zhao Lauren L   Joseph George G   Cheng Hung-Yuan HY   Gupta Subhajit S   Shah Nirmish N  

BMJ open 20200917 9


<h4>Objectives</h4>Treatment options for preventing vaso-occlusive crises (VOC) among patients with sickle cell disease (SCD) are limited, especially if hydroxyurea treatment has failed or is contraindicated. A systematic literature review (SLR) and network meta-analysis (NMA) were conducted to evaluate the efficacy and safety of crizanlizumab for older adolescent and adult (≥16 years old) SCD patients.<h4>Methods</h4>The SLR included randomised controlled trials (RCTs) and uncontrolled studies.  ...[more]

Similar Datasets

| S-EPMC5481200 | biostudies-literature
| S-EPMC6292161 | biostudies-literature
| S-EPMC10027508 | biostudies-literature
| S-EPMC6171302 | biostudies-literature
| S-EPMC9928781 | biostudies-literature
| S-EPMC5631172 | biostudies-literature
| S-EPMC6072976 | biostudies-literature
| S-EPMC7754589 | biostudies-literature
| S-EPMC8110229 | biostudies-literature
| S-EPMC7602310 | biostudies-literature